Fig. 3
From: Genetically engineered membrane-based nanoengagers for immunotherapy of pancreatic cancer
Tumor targeting and biodistribution. (a) Representative in vivo fluorescence imaging of biodistribution at the indicated time points after i.v. injection of Nano/TM, Nano/CD40, Nano/CLDN18.2 and NanoBE. Tumors were indicated by black circle. (b) Mean signal intensity of tumors following administration of the particles at the indicated time points. (c) Representative ex vivo fluorescent images of major organs at 48 h post-injection. (d) Relative signal intensity of each organ normalized to that of the muscle at 48 h post-injection. Statistical analysis between the indicated groups was performed using two-way ANOVA with Tukey’s multiple comparisons test. ****p < 0.0001